Zenkuda met the primary endpoint (p=0.0007) with 54% of patients on 6-month dosing. tabirafusp-ted also met endpoints. BLA submission planned for Q4 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
